创新医疗(002173) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥202,362,714.02, an increase of 0.26% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥11,814,553.98, a decrease of 9.79% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,761,551.20, down 10.13% from the previous year[3]. - The basic and diluted earnings per share were both -¥0.0268, reflecting a decrease of 11.20% compared to the same period last year[3]. - The net profit for the current period was a loss of ¥27,696,859.76, compared to a loss of ¥14,256,798.12 in the previous period, indicating a deterioration in profitability[15]. - The operating profit (loss) for the current period was reported at -¥28,154,976.79, compared to -¥9,919,029.87 in the previous period[14]. - The total profit (loss) for the current period was -¥29,006,505.08, compared to -¥11,341,862.31 in the previous period, indicating a significant increase in losses[15]. - Basic and diluted earnings per share were both reported at -0.0631, worsening from -0.0319 in the previous period[15]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,219,996,464.06, a decrease of 2.69% from the end of the previous year[3]. - The total assets decreased from CNY 2,281,472,772.53 at the beginning of the period to CNY 2,219,996,464.06 at the end of the period, reflecting a decline of approximately 2.7%[12]. - Cash and cash equivalents decreased from CNY 563,083,485.71 to CNY 547,164,141.38, a reduction of about 2.9%[11]. - Accounts receivable increased from CNY 102,840,031.95 to CNY 111,110,613.96, representing an increase of approximately 8.3%[11]. - Inventory decreased from CNY 41,805,047.04 to CNY 38,960,002.85, a decline of about 6.7%[11]. - Total liabilities decreased from CNY 410,385,658.35 to CNY 376,606,209.64, a reduction of approximately 8.2%[12]. - The company's equity attributable to shareholders decreased from CNY 1,870,152,115.48 to CNY 1,842,307,968.32, reflecting a decline of about 1.5%[13]. - The company reported a net loss of CNY 1,332,081,858.74 in retained earnings, compared to a loss of CNY 1,304,237,711.58 in the previous period[13]. - The company’s short-term borrowings increased from CNY 30,170,500.00 to CNY 41,051,332.73, an increase of approximately 36.1%[12]. - The company’s long-term investments decreased from CNY 15,219,218.88 to CNY 13,101,441.86, a decline of about 13.9%[11]. - The company’s total current assets decreased from CNY 733,059,385.69 to CNY 717,701,375.28, a reduction of approximately 2.1%[11]. Cash Flow - The net cash flow from operating activities was ¥15,638,753.63, down 45.16% compared to the same period last year[6]. - Cash flow from operating activities was ¥597,551,557.61, down from ¥601,347,530.39 in the previous period, reflecting a decrease of about 0.3%[15]. - The net cash flow from operating activities for Q3 2024 was 15,638,753.63, a decrease of 45.1% compared to 28,517,936.69 in Q3 2023[17]. - The company reported a total cash outflow from operating activities of 595,094,531.43, slightly up from 590,058,096.01 in the same period last year[17]. - Total cash inflow from investment activities was 413,191,443.62, while cash outflow was 518,800,661.50, resulting in a net cash flow of -105,609,217.88 for investment activities[17]. - Cash inflow from financing activities amounted to 51,138,089.76, an increase from 30,404,647.29 in the previous year[17]. - The net cash flow from financing activities was 7,996,259.87, compared to 650,826.72 in Q3 2023, indicating a significant increase[17]. - The total cash and cash equivalents at the end of Q3 2024 were 167,045,430.63, down from 620,884,321.32 at the end of Q3 2023[17]. - The company received tax refunds totaling 1,052,496.99 during the quarter[17]. - Payments to employees amounted to 263,618,338.17, an increase from 256,338,193.10 in Q3 2023[17]. Shareholder Information - The company reported a total of 45,164 common shareholders at the end of the reporting period[7]. - The largest shareholder, Chen Xiaying, holds 17.59% of the shares, amounting to 77,616,997 shares[7]. Operational Insights - The company experienced a significant decrease in gross profit margin due to reduced medical service reimbursement rates[6]. - The company is focusing on expanding its market presence and improving operational efficiency to enhance profitability in the future[6]. Audit Status - The report for Q3 2024 was not audited[18].